WallStreetZenWallStreetZen

NASDAQ: TMDX
Transmedics Group Inc Stock

$82.00-6.71 (-7.56%)
Updated Feb 28, 2024
TMDX Price
$82.00
Fair Value Price
-$0.08
Market Cap
$2.68B
52 Week Low
$36.42
52 Week High
$99.63
P/E
-106.49x
P/B
19.55x
P/S
10.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$241.62M
Earnings
-$25.03M
Gross Margin
63.8%
Operating Margin
-6.57%
Profit Margin
-10.4%
Debt to Equity
4.15
Operating Cash Flow
-$13M
Beta
1.3
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TMDX Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TMDX ($82.00) is overvalued by 98,940.08% relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TMDX ($82.00) is not significantly undervalued (98,940.08%) relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TMDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TMDX due diligence checks available for Premium users.

Be the first to know about important TMDX news, forecast changes, insider trades & much more!

TMDX News

Valuation

TMDX fair value

Fair Value of TMDX stock based on Discounted Cash Flow (DCF)
Price
$82.00
Fair Value
-$0.08
Undervalued by
98,940.08%
TMDX ($82.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TMDX ($82.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TMDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TMDX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-106.49x
Industry
32.47x
Market
35.52x

TMDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
19.55x
Industry
4x
TMDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TMDX's financial health

Profit margin

Revenue
$81.2M
Net Income
$4.0M
Profit Margin
5%
TMDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TMDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$706.0M
Liabilities
$568.8M
Debt to equity
4.15
TMDX's short-term assets ($510.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMDX's long-term liabilities ($513.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$8.3M
Investing
-$41.8M
Financing
$924.0k
TMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TMDX vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
TMDX$2.68B-7.56%-106.49x19.55x
PRCT$2.52B-2.68%-22.05x8.97x
CNMD$2.45B-1.09%37.90x2.94x
LIVN$2.97B-1.45%1,101.80x2.42x
QDEL$3.01B-3.63%-167.04x0.61x

Transmedics Group Stock FAQ

What is Transmedics Group's quote symbol?

(NASDAQ: TMDX) Transmedics Group trades on the NASDAQ under the ticker symbol TMDX. Transmedics Group stock quotes can also be displayed as NASDAQ: TMDX.

If you're new to stock investing, here's how to buy Transmedics Group stock.

What is the 52 week high and low for Transmedics Group (NASDAQ: TMDX)?

(NASDAQ: TMDX) Transmedics Group's 52-week high was $99.63, and its 52-week low was $36.42. It is currently -17.7% from its 52-week high and 125.15% from its 52-week low.

How much is Transmedics Group stock worth today?

(NASDAQ: TMDX) Transmedics Group currently has 32,715,316 outstanding shares. With Transmedics Group stock trading at $82.00 per share, the total value of Transmedics Group stock (market capitalization) is $2.68B.

Transmedics Group stock was originally listed at a price of $22.36 in May 2, 2019. If you had invested in Transmedics Group stock at $22.36, your return over the last 4 years would have been 266.73%, for an annualized return of 38.38% (not including any dividends or dividend reinvestments).

How much is Transmedics Group's stock price per share?

(NASDAQ: TMDX) Transmedics Group stock price per share is $82.00 today (as of Feb 28, 2024).

What is Transmedics Group's Market Cap?

(NASDAQ: TMDX) Transmedics Group's market cap is $2.68B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Transmedics Group's market cap is calculated by multiplying TMDX's current stock price of $82.00 by TMDX's total outstanding shares of 32,715,316.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.